Komori
Other Disclosures4884Kringle Pharma,Inc.Pharmaceuticals

Notice of Update to the Financial Results Report for the Second Quarter of the Fiscal Year Ending September 2026

The full report on second-quarter earnings for the fiscal year ending September 2026, prepared by 株式会社シェアードリサーチ, has been updated.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

Report on Second-Quarter Earnings for the Fiscal Year Ending September 2026 (Full Report)
Applicable field (uses covered by this announcement)

Corporate research and investment decisions by investors

Launch date8 June 2026 (report update date; actual)
Relationship between the counterparty and the company
Kringle Pharma,Inc.4884
Relationship with the Company

株式会社シェアードリサーチ prepares and updates earnings reports on the Company from an independent third-party perspective. Details of the capital, personnel, and business relationships are not disclosed.

CounterpartyShared Research Inc.

A company that provides research reports on companies. The location, representative, capital, and year of establishment are not disclosed in this document.

Offering price

Free

The company does not address Contract Value / Impact on Business Performance.

Source (materials cited by the company)

Shared Research Inc.

Announced details
ItemDetails
Names of Products / Services CoveredReport on Second-Quarter Earnings for the Fiscal Year Ending September 2026 (Full Report)
CounterpartyShared Research Inc.
Counterparty overviewA company that provides research reports on companies. The location, representative, capital, and year of establishment are not disclosed in this document.
Relationship with the Company株式会社シェアードリサーチ prepares and updates earnings reports on the Company from an independent third-party perspective. Details of the capital, personnel, and business relationships are not disclosed.
Offering priceFree
Launch date8 June 2026 (report update date; actual)
Applicable areaCorporate research and investment decisions by investors
SourceShared Research Inc.
Items this document does not state (10)
Contract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To improve the efficiency of investors’ research on the Company and enable constructive dialogue with the Company. The update is also intended to deepen investors’ understanding of the Company and serve as a reference for investment decisions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Update to the Financial Results Report for the Second Quarter of the Fiscal Year Ending September 2026 | Kringle Pharma,Inc. (4884) timely disclosure | Komori